Citations

Clear

23 citation(s) found for "Sill, J".

Working Up Group 4 Equivocal HER2 Samples Tested by Fluorescence in Situ Hybridization in a Reference Laboratory Setting: Past, Present, and Future
Geiersbach, Katherine B. , Meyer, Reid G., Sill, Daniel R, Mounajjed, Taofic, Chen, Beiyun, Sukov, William R. , Jenkins, Robert B. , Geiersbach, Katherine

Mayo Clinic

Journal of Clinical Oncology | November 26, 2019 | Volume: 38 | Issue: 2 | Pages: 175-176

10.1200/jco.19.02482 | PMID 31770062 Get It

Inhaled TRIM72 Protein Protects Ventilation Injury to the Lung through Injury-guided Cell Repair
Nagre, Nagaraja N. , Cong, Xiaofei, Fu, Hongyun , Pepper, Ian, Warren, Seth , Sill, Joshua , Hubmayr, Rolf D., Zhao, Xiaoli , Ji, Hong‐Long , Schreiber, John R. , Fu, Hongyun

Mayo Clinic

American Journal of Respiratory Cell and Molecular Biology | June 29, 2018 | Volume: 59 | Issue: 5 | Pages: 635-647

10.1165/rcmb.2017-0364oc | PMID 29958015 Get It

Abstract Studies showed that TRIM72 is essential for repair of alveolar cell membrane disruptions, and exogenous recombinant human TRIM72 protein (rhT72) demonstrated tissue-mending properties in animal models of tissue injury. Here we examine the mechanisms of rhT72-mediated lung cell protection in vitro and test the efficacy of inhaled rhT72 in reducing tissue pathology in a mouse model of ventilator-induced lung injury. In vitro lung cell injury was induced by glass beads and stretching. Ventilator-induced lung injury was modeled by injurious ventilation at 30 ml/kg tidal volume. Affinity-purified rhT72 or control proteins were added into culture medium or applied through nebulization. Cellular uptake and in vivo distribution of rhT72 were detected by imaging and immunostaining. Exogenous rhT72 maintains membrane integrity of alveolar epithelial cells subjected to glass bead injury in a dose-dependent manner. Inhaled rhT72 decreases the number of fatally injured alveolar cells, and ameliorates tissue-damaging indicators and cell injury markers after injurious ventilation. Using in vitro stretching assays, we reveal that rhT72 improves both cellular resilience to membrane wounding and membrane repair after injury. Image analysis detected rhT72 uptake by rat alveolar epithelial cells, which can be inhibited by a cholesterol-disrupting agent. In addition, inhaled rhT72 distributes to the distal lungs, where it colocalizes with phosphatidylserine detection on nonpermeabilized lung slices to label wounded cells. In conclusion, our study showed that inhaled rhT72 accumulates in injured lungs and protects lung tissue from ventilator injury, the mechanisms of which include improving cell resilience to membrane wounding, localizing to injured membrane, and augmenting membrane repair.
Endothelial L-arginine pathway and relaxations to vasopressin in canine basilar artery
Sill, J. C., Katušić, Zvonimir S. , Cosentino, Francesco

Mayo Clinic

American Journal of Physiology-Heart and Circulatory Physiology | December 21, 2017 | Volume: 264 | Issue: 2 | Pages: H413-H418

10.1152/ajpheart.1993.264.2.h413 | PMID 8383455 Get It

Experiments were designed to determine the role of the L-arginine pathway in endothelium-dependent relaxations to vasopressin. The effects of L-arginine analogues NG-nitro-L-arginine (L-NNA), NG-nitro-L-arginine methyl ester (L-NAME), and NG-monomethyl-L-arginine (L-NMMA) on basal and vasopressin-induced activity of nitric oxide synthase were studied in isolated canine basilar arteries. Rings with and without endothelium were suspended for isometric tension recording in Krebs-Ringer bicarbonate solution bubbled with 94% O2-6% CO2 (37 degrees C, pH 7.4). Radioimmunoassay was used to determine the level of guanosine 3',5'-cyclic monophosphate (cGMP). All experiments were performed in the presence of indomethacin, a cyclooxygenase inhibitor. L-NAME and L-NMMA caused endothelium-dependent contractions and inhibited basal production of cGMP. In contrast, L-NNA did not affect basal tone or basal production of cGMP. L-Arginine analogues inhibited relaxations to vasopressin but did not affect relaxations to a nitric oxide donor, molsidomine (SIN-1). The effects of L-NNA, L-NAME, and L-NMMA were reversed in the presence of L-arginine. The relaxations to vasopressin were associated with an increase of cGMP levels in the arterial wall. This effect of vasopressin was inhibited in the presence of L-NNA. These studies suggest that the relaxations to vasopressin are mediated by activation of the endothelial L-arginine pathway, leading to increased production of nitric oxide, with subsequent activation of guanylate cyclase in smooth muscle cells. In canine basilar artery, L-NAME and L-NMMA are nonselective inhibitors of both basal and stimulated production of nitric oxide, whereas L-NNA selectively inhibits vasopressin-induced activation of the L-arginine pathway.
Incorporation of bevacizumab in the treatment of recurrent and metastatic cervical cancer: A phase III randomized trial of the Gynecologic Oncology Group.
Tewari, Krishnansu S. , Sill, Michael W. , Long, Harry J., Reid, Thomas , Michael, Helen E., Monk, Bradley J. , Ramondetta, Lois Michelle , Landrum, Lisa M. , Oaknin, Ana , Leitão, Mario M.

Mayo Clinic

Journal of Clinical Oncology | February 24, 2017 | Volume: 31 | Issue: 18_suppl | Pages: 3-3

10.1200/jco.2013.31.18_suppl.3 Get It

3 Background: Vascular endothelial growth factor (VEGF) promotes angiogenesis, a mediator of disease progression in cervical cancer. Bevacizumab (B), a humanized anti-VEGF monoclonal antibody, has shown single-agent activity in pretreated recurrent disease. We aimed to evaluate B in chemotherapy (CTX)-naive recurrent/persistent/metastatic cervical cancer. Methods: Using a 2x2 factorial design, patients were randomly assigned to CTX with or without B 15 mg/kg. The CTX regimens included cisplatin 50 mg/m2 plus paclitaxel 135-175 mg/m2 and topotecan 0.75 mg/m2 d1-3 plus paclitaxel 175 mg/m2d1. Cycles were repeated every 21 days until disease progression, unacceptable toxicity, or complete response. Overall survival (OS) was the primary endpoint with a reduction in the hazard of death by 30% using anti-VEGF therapy considered important (90% power, 1-sided alpha=2.5%). Final analysis was planned when 346 deaths were observed. Results: 452 patients were accrued from 4/6/09 to 1/3/12. The scheduled interim analysis occurred after 174 patients had died and showed that the topotecan-paclitaxel backbone was not superior to the cisplatin-paclitaxel backbone. A second interim analysis was conducted after 271 deaths. A total of 225 patients received CTX alone and 227 patients received CTX plus B. The randomized treatment groups were similar with regard to age, histology, performance status, previous platinum as a radiosensitizer, and recurrence, persistence, or advanced disease. The B-to-no-B hazard ratio (HR) of death was 0.71 (97.6% CI 0.54-0.95; 1-sided p=0.0035). Median survival was 17 m (CTX plus B) and 13.3 m (CTX alone). The RR were 48% (CTX plus B) and 36% (CTX alone) (p=0.0078). Treatment with B was associated with more grade 3-4 bleeding (5 vs 1%) thrombosis/embolism (9 vs 2%), and GI fistula (3 vs 0%). Conclusions: For the first time a targeted agent significantly improved OS in gynecologic cancer. The second interim analysis crossed the boundary for efficacy, warranting early release of this information. The nearly 4-month increase in median OS with the addition of B to CTX in women with recurrent cervical cancer is considered to be clinically significant. Clinical trial information: NCT00803062.
Prospective Validation of Pooled Prognostic Factors in Women with Advanced Cervical Cancer Treated with Chemotherapy with/without Bevacizumab: NRG Oncology/GOG Study
Tewari, Krishnansu S. , Sill, Michael W. , Monk, Bradley J. , Penson, Richard T. , Long, Harry J., Poveda, Andrés , Landrum, Lisa M. , Brown, Jubilee , Reid, Thomas , Michael, Helen E., Moore, David H. , Leitão, Mario M.

Mayo Clinic

Clinical Cancer Research | December 15, 2015 | Volume: 21 | Issue: 24 | Pages: 5480-5487

10.1158/1078-0432.ccr-15-1346 | PMID 26672085 Get It

Abstract Purpose: In the randomized phase III trial, Gynecologic Oncology Group (GOG) protocol 240, the incorporation of bevacizumab with chemotherapy significantly increased overall survival (OS) in women with advanced cervical cancer. A major objective of GOG-240 was to prospectively analyze previously identified pooled clinical prognostic factors known as the Moore criteria. Experimental Design: Potential negative factors included black race, performance status 1, pelvic disease, prior cisplatin, and progression-free interval <365 days. Risk categories included low-risk (0–1 factor), mid-risk (2–3 factors), and high-risk (4–5 factors). Each test of association was conducted at the 5% level of significance. Logistic regression and survival analysis was used to determine whether factors were prognostic or could be used to guide therapy. Results: For the entire population (n = 452), high-risk patients had significantly worse OS (P < 0.0001). The HRs of death for treating with topotecan in low-risk, mid-risk, and high-risk subsets are 1.18 [95% confidence interval (CI), 0.63–2.24], 1.11 (95% CI, 0.82–1.5), and 0.84 (95% CI, 0.50–1.42), respectively. The HRs of death for treating with bevacizumab in low-risk, mid-risk, and high-risk subsets are 0.96 (95% CI, 0.51–1.83; P = 0.9087), 0.673 (95% CI, 0.5–0.91; P = 0.0094), and 0.536 (95% CI, 0.32–0.905; P = 0.0196), respectively. Conclusions: This is the first prospectively validated scoring system in cervical cancer. The Moore criteria have real-world clinical applicability. Toxicity concerns may justify omission of bevacizumab in some low-risk patients where survival benefit is small. The benefit to receiving bevacizumab appears to be greatest in the moderate- and high-risk subgroups (5.8-month increase in median OS). Clin Cancer Res; 21(24); 5480–7. ©2015 AACR.
Complexities of Basic Science
Sill, J. C., Sill, John C

Mayo Clinic

Anesthesiology | December 18, 2013 | Volume: 120 | Issue: 1 | Pages: 238-238

10.1097/aln.0000000000000057 | PMID 24398736 Get It

Human Platelet Ca2+Mobilization, Glycoprotein IIb/IIIa Activation, and Experimental Coronary Thrombosis In Vivo in Dogs Are All Inhibited by the Inotropic Agent Amrinone
Sill, J. C., Bertha, B. G., Berger, Ines H., Uhl, C., Folts, John D., Nugent, Michael

Mayo Clinic

Circulation | June 12, 2012 | Volume: 96 | Issue: 5 | Pages: 1647-1653

10.1161/01.cir.96.5.1647 | PMID 9315560 Get It

BackgroundInotropic drugs are often used to treat acute, severe heart failure resulting from acute myocardial infarction and other unstable coronary artery syndromes. However, catecholamine inotropic agents may potentiate coronary thrombosis via a platelet α2-adrenergic mechanism, thus exacerbating the original problem. The present studies were designed to determine whether the nonadrenergic inotropic and vasodilator drug amrinone, which elevates platelet cAMP levels, would both inhibit human platelet Ca2+mobilization and adhesion molecule expression ex vivo and protect against experimental coronary thrombosis in vivo in dogs.Methods and ResultsHuman platelets in suspension were preincubated with amrinone 2.5 to 15 μg/mL; stimulated with the agonists thrombin 0.1 U/mL, ADP 10−6mol/L, or arginine vasopressin 10−7mol/L; and studied for Ca2+mobilization, glycoprotein IIb/IIIa activation, and P-selectin expression by fluorescent flow cytometry methods. Experimental coronary thrombosis in vivo was studied in an open-chest dog model with critical coronary artery stenosis and deep vessel wall injury. Results showed that at the cellular level, amrinone inhibited agonist-induced Ca2+mobilization and had modest inhibitory effects on adhesion molecule expression. In vivo in dogs, intravenous amrinone 2 mg/kg plus infusion at 20 μg·kg−1·min−1completely abolished coronary thrombosis.ConclusionsThe fact that amrinone inhibited human platelet activation at the cellular level and protected against experimental coronary thrombosis in vivo in dogs suggests a potentially advantageous antithrombotic action for this inotropic and vasodilator drug.
Role of superoxide anions in the mediation of endothelium-dependent contractions.
Sill, J. C., Katušić, Zvonimir S. , Cosentino, Francesco

Mayo Clinic

Hypertension | June 12, 2012 | Volume: 23 | Issue: 2 | Pages: 229-235

10.1161/01.hyp.23.2.229 | PMID 8307634 Get It

We designed experiments to characterize the role of superoxide anions in the mediation of endothelium-dependent contractions in isolated canine basilar arteries. Rings with and without endothelium were suspended for isometric tension recording in Krebs-Ringer bicarbonate solution bubbled with 94% O2-6% CO2 (37 degrees C, pH 7.4). Radioimmunoassay was used to determine the levels of cyclic GMP and cyclic AMP. Calcium ionophore A23187 (10(-9) to 10(-6) mol/L) caused concentration-dependent contractions. The removal of endothelium abolished the effect of A23187. Contractions to A23187 were reversed into relaxations in the presence of superoxide dismutase (150 U/mL) or the prostaglandin H2/thromboxane A2 receptor antagonist SQ29548 (10(-6) mol/L). NG-nitro-L-arginine methyl ester (3 x 10(-4) mol/L) augmented contractions to A23187. In rings with endothelium, A23187 (3 x 10(-7) mol/L) significantly increased levels of both cyclic AMP and cyclic GMP. Indomethacin (10(-5) mol/L) inhibited stimulatory effects of A23187 on cyclic AMP production. In contrast, indomethacin augmented A23187-induced production of cyclic GMP. Selective augmentation of cyclic GMP production by indomethacin appears to be due to protection of nitric oxide or a closely related molecule released following translocation of calcium into endothelial cells. Our findings suggest that (1) an increased concentration of calcium in endothelial cells may activate both cyclooxygenase and the L-arginine/nitric oxide pathway, (2) arachidonic acid metabolism via cyclooxygenase is a source of superoxide anions, and (3) superoxide anions may be responsible for impairment of balance between relaxing and contracting factors leading to contraction of underlying smooth muscle cells.
High-dose Droperidol Protects against Experimental Coronary Thrombosis in Dogs and Pigs and Attenuates Aggregation of Porcine Platelets and Ca2+ Mobilization in Human Platelets
Bertha, B. G., Sill, J. C., Berger, Ines H., Folts, John D., Milde, James H.

Mayo Clinic

Anesthesiology | October 5, 2006 | Volume: 78 | Issue: 4 | Pages: 733-743

10.1097/00000542-199304000-00017 | PMID 8466073 Get It

Fentanyl Is Devoid of Major Effects on Coronary Vasoreactivity and Myocardial Metabolism in Experimental Animals
Blaise, G., Witzelling, T. M., Sill, J. C., Vinay, P., Vanhoutte, Paul M.

Mayo Clinic

Anesthesiology | October 2, 2006 | Volume: 72 | Issue: 3 | Pages: 535-541

10.1097/00000542-199003000-00023 | PMID 2310036 Get It